Efficacy of vasodilators in the treatment of heart failure

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Vasodilator drugs have been undergoing evaluation as therapy for heart failure for > 20 years. It has become clear that hemodynamic benefits, short-term improvement in exercise tolerance and long-term alteration in mortality are independent end points for efficacy of these drugs. Differing hemodynamic responses, variable effects on exercise capacity and differential effect on mortality of various vasodilator compounds raise the likelihood that vascular smooth muscle relaxation is not the sole mechanism of action of these drugs. Neurohormonal and aitiproliferative effects of these agents may play a key rote in the long-term response. Data from trials indicate that the vasodilator combinatiom of hydralazine and isosorbide dinitrate as well as converting enzyme inhibitors can favorably affect all end points. The global efficacy of other vasodilators, such as calcium antagonists, has not yet been fully evaluated.

Original languageEnglish (US)
JournalJournal of the American College of Cardiology
Volume22
Issue number4 SUPPL. 1
DOIs
StatePublished - Jan 1 1993

Fingerprint

Treatment Failure
Vasodilator Agents
Heart Failure
Hemodynamics
Isosorbide Dinitrate
Hydralazine
Muscle Relaxation
Exercise Tolerance
Mortality
Enzyme Inhibitors
Vascular Smooth Muscle
Pharmaceutical Preparations
Calcium
Therapeutics

Cite this

Efficacy of vasodilators in the treatment of heart failure. / Cohn, Jay N.

In: Journal of the American College of Cardiology, Vol. 22, No. 4 SUPPL. 1, 01.01.1993.

Research output: Contribution to journalArticle

@article{1f23f4dc4f9d4f9999a75189809c52bc,
title = "Efficacy of vasodilators in the treatment of heart failure",
abstract = "Vasodilator drugs have been undergoing evaluation as therapy for heart failure for > 20 years. It has become clear that hemodynamic benefits, short-term improvement in exercise tolerance and long-term alteration in mortality are independent end points for efficacy of these drugs. Differing hemodynamic responses, variable effects on exercise capacity and differential effect on mortality of various vasodilator compounds raise the likelihood that vascular smooth muscle relaxation is not the sole mechanism of action of these drugs. Neurohormonal and aitiproliferative effects of these agents may play a key rote in the long-term response. Data from trials indicate that the vasodilator combinatiom of hydralazine and isosorbide dinitrate as well as converting enzyme inhibitors can favorably affect all end points. The global efficacy of other vasodilators, such as calcium antagonists, has not yet been fully evaluated.",
author = "Cohn, {Jay N}",
year = "1993",
month = "1",
day = "1",
doi = "10.1016/0735-1097(93)90477-I",
language = "English (US)",
volume = "22",
journal = "Journal of the American College of Cardiology.",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "4 SUPPL. 1",

}

TY - JOUR

T1 - Efficacy of vasodilators in the treatment of heart failure

AU - Cohn, Jay N

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Vasodilator drugs have been undergoing evaluation as therapy for heart failure for > 20 years. It has become clear that hemodynamic benefits, short-term improvement in exercise tolerance and long-term alteration in mortality are independent end points for efficacy of these drugs. Differing hemodynamic responses, variable effects on exercise capacity and differential effect on mortality of various vasodilator compounds raise the likelihood that vascular smooth muscle relaxation is not the sole mechanism of action of these drugs. Neurohormonal and aitiproliferative effects of these agents may play a key rote in the long-term response. Data from trials indicate that the vasodilator combinatiom of hydralazine and isosorbide dinitrate as well as converting enzyme inhibitors can favorably affect all end points. The global efficacy of other vasodilators, such as calcium antagonists, has not yet been fully evaluated.

AB - Vasodilator drugs have been undergoing evaluation as therapy for heart failure for > 20 years. It has become clear that hemodynamic benefits, short-term improvement in exercise tolerance and long-term alteration in mortality are independent end points for efficacy of these drugs. Differing hemodynamic responses, variable effects on exercise capacity and differential effect on mortality of various vasodilator compounds raise the likelihood that vascular smooth muscle relaxation is not the sole mechanism of action of these drugs. Neurohormonal and aitiproliferative effects of these agents may play a key rote in the long-term response. Data from trials indicate that the vasodilator combinatiom of hydralazine and isosorbide dinitrate as well as converting enzyme inhibitors can favorably affect all end points. The global efficacy of other vasodilators, such as calcium antagonists, has not yet been fully evaluated.

UR - http://www.scopus.com/inward/record.url?scp=0027360574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027360574&partnerID=8YFLogxK

U2 - 10.1016/0735-1097(93)90477-I

DO - 10.1016/0735-1097(93)90477-I

M3 - Article

C2 - 8376683

AN - SCOPUS:0027360574

VL - 22

JO - Journal of the American College of Cardiology.

JF - Journal of the American College of Cardiology.

SN - 0735-1097

IS - 4 SUPPL. 1

ER -